ESTRO 2025 - Abstract Book

S930

Clinical – Head & neck

ESTRO 2025

[2]Al-Rajhi NM, Khalil EM, Ahmad S, et al. Low-dose fractionated radiation with induction docetaxel and cisplatin followed by concurrent cisplatin and radiation therapy in locally advanced nasopharyngeal cancer: A randomized phase II-III trial. Hematol Oncol Stem Cell Ther.2020, 403-410. [3]Hu YJ, Lu, TZ, Guo, QJ, et al. The role of radiologic extranodal extension in predicting prognosis and chemotherapy benefit for T1-2 N1 nasopharyngeal carcinoma: A multicenter retrospective study. RADIOTHER ONCOL. 2022;

245

Digital Poster Tubarial gland sparing for oropharyngeal cancer: Feasibility with Intensity Modulated Proton Therapy & Intensity Modulated Radiation Therapy Sreenija Yarlagadda 1 , Robert M Rohe 1 , Valeriane McNeill 1 , Joanna R Nemec 1 , Chelsea P. Tohtz 1 , Zachary W. Fellows 1 , Nicole McAllister 1 , Amy E. Rzepczynski 1 , Kristen A. McConnell 1 , Noah S. Kalman 1,2 1 Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, USA. 2 Radiation Oncology, Herbert Wertheim College of Medicine, Florida International University, Miami, USA Purpose/Objective: The recently discovered tubarial glands may serve as an organ at risk (OAR) in head and neck radiation therapy (RT). 1 In this study, we report the feasibility of sparing tubarial glands in oropharyngeal cancer using Intensity Modulated Proton Therapy (IMPT) and Intensity Modulated Radiation Therapy (IMRT). Material/Methods: After Institutional Review Board approval, seventeen patients with OPSCC who received definitive RT were included in the study. Baseline characteristics were extracted from electronic medical records. Clinical plans were generated using IMPT and IMRT with institutional dose constraints. Tubarial glands were then delineated for each patient and the plans were re-optimized to minimize the mean dose to tubarial glands to as low as reasonably achievable, respecting the target coverage. (Figure 1) The clinical and re-optimized plans were compared for tubarial gland mean dose, target coverage (D 99% for High Risk-, Intermediate Risk-, and Low Risk- Clinical Target Volumes [HR-CTV, IR-CTV, LR-CTV]), and other OAR doses.